UNDERSTANDING HOW EPITOPE BINDING INFLUENCES ANTIBODY DEPENDENT COMPLEMENT ENGAGEMENT FOR THERAPY OF B-CELL MALIGNANCIES

被引：0
|
作者：
Bondza, S. [1 ,2 ]
Buijs, J. [1 ,2 ]
Lux, A. [3 ]
机构：
[1] Uppsala Univ, Uppsala, Sweden
[2] Ridgeview Instruments, Uppsala, Sweden
[3] Friedrich Alexander Univ, Erlangen, Germany
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-ITOC9.2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
03.06
引用
收藏
页码：A1 / A1
页数：1
相关论文
共 50 条
  • [1] Monoclonal antibody therapy for B-cell malignancies
    Cheson, Bruce D.
    SEMINARS IN ONCOLOGY, 2006, 33 (02) : S2 - S14
  • [2] Complement Activation in the Treatment of B-Cell Malignancies
    Zent, Clive S.
    Pinney, Jonathan J.
    Chu, Charles C.
    Elliott, Michael R.
    ANTIBODIES, 2020, 9 (04) : 1 - 14
  • [3] Immunogenetic therapy for B-cell malignancies
    Kipps, TJ
    Chu, P
    Wierda, WG
    SEMINARS IN ONCOLOGY, 2000, 27 (06) : 104 - 109
  • [4] The future of CD20 monoclonal antibody therapy in B-cell malignancies
    Czuczman, Myron S.
    Gregory, Stephanie A.
    LEUKEMIA & LYMPHOMA, 2010, 51 (06) : 983 - 994
  • [5] Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies
    Stasilojc, Grzegorz
    Felberg, Anna
    Urban, Aleksandra
    Kowalska, Daria
    Ma, Shuo
    Blom, Anna M.
    Lundin, Jeanette
    Osterborg, Anders
    Okroj, Marcin
    JOURNAL OF IMMUNOLOGICAL METHODS, 2020, 476
  • [6] A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
    Cardarelli, Pina M.
    Rao-Naik, Chetana
    Chen, Sharline
    Huang, Haichun
    Pham, Amie
    Moldovan-Loomis, Maria-Cristina
    Pan, Chin
    Preston, Ben
    Passmore, David
    Liu, Jie
    Kuhne, Michelle R.
    Witte, Alison
    Blanset, Diann
    King, David J.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (02) : 257 - 265
  • [7] A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
    Pina M. Cardarelli
    Chetana Rao-Naik
    Sharline Chen
    Haichun Huang
    Amie Pham
    Maria-Cristina Moldovan-Loomis
    Chin Pan
    Ben Preston
    David Passmore
    Jie Liu
    Michelle R. Kuhne
    Alison Witte
    Diann Blanset
    David J. King
    Cancer Immunology, Immunotherapy, 2010, 59 : 257 - 265
  • [8] Docking of B-cell epitope antigen to specific hepatitis B antibody
    R. Rajkannan
    E. J. Padma Malar
    Journal of Chemical Sciences, 2007, 119 : 553 - 558
  • [9] Docking of B-cell epitope antigen to specific hepatitis B antibody
    Rajkannan, R.
    Malar, E. J. Padma
    JOURNAL OF CHEMICAL SCIENCES, 2007, 119 (05): : 553 - 558
  • [10] T cell-dependent bispecific antibody anti-CD79b/CD3 as a potential therapy for B-cell malignancies
    Wang, Peiyin
    Hristopoulos, Maria
    Clark, Robyn
    Chen, Yvonne
    Ellerman, Diego
    Mathieu, Mary
    Spiess, Christoph
    Li, Jessica
    Chalouni, Cecile
    Sukumaran, Siddharth
    Stefanich, Eric
    Wallin, Jeffrey
    Li, Robert
    Zabka, Tanja
    Totpal, Klara
    Dennis, Mark
    Ebens, Allen
    Gould, Stephen
    Polson, Andrew
    Sun, Liping Laura
    CANCER RESEARCH, 2017, 77
12345